JP2022517461A - Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 - Google Patents

Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 Download PDF

Info

Publication number
JP2022517461A
JP2022517461A JP2021512883A JP2021512883A JP2022517461A JP 2022517461 A JP2022517461 A JP 2022517461A JP 2021512883 A JP2021512883 A JP 2021512883A JP 2021512883 A JP2021512883 A JP 2021512883A JP 2022517461 A JP2022517461 A JP 2022517461A
Authority
JP
Japan
Prior art keywords
csf
antibody
hgm
region
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512883A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020055932A5 (https=
JP2022517461A5 (https=
Inventor
デュラント、キャメロン
チャペル、デール
Original Assignee
ヒューマニゲン インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/149,346 external-priority patent/US10870703B2/en
Priority claimed from US16/204,220 external-priority patent/US10899831B2/en
Priority claimed from US16/248,762 external-priority patent/US10927168B2/en
Priority claimed from US16/283,694 external-priority patent/US11130805B2/en
Application filed by ヒューマニゲン インコーポレイティッド filed Critical ヒューマニゲン インコーポレイティッド
Publication of JP2022517461A publication Critical patent/JP2022517461A/ja
Publication of JPWO2020055932A5 publication Critical patent/JPWO2020055932A5/ja
Publication of JP2022517461A5 publication Critical patent/JP2022517461A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021512883A 2018-09-10 2019-09-10 Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 Pending JP2022517461A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862729043P 2018-09-10 2018-09-10
US62/729,043 2018-09-10
US16/149,346 US10870703B2 (en) 2017-10-02 2018-10-02 Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
PCT/US2018/053933 WO2019070680A2 (en) 2017-10-02 2018-10-02 METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING GM-CSF ANTAGONIST
USPCT/US2018/053933 2018-10-02
US16/149,346 2018-10-02
US16/204,220 2018-11-29
US16/204,220 US10899831B2 (en) 2017-10-02 2018-11-29 Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US16/248,762 US10927168B2 (en) 2017-10-02 2019-01-15 Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US16/248,762 2019-01-15
US16/283,694 2019-02-22
US16/283,694 US11130805B2 (en) 2017-10-02 2019-02-22 Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
PCT/US2019/050494 WO2020055932A2 (en) 2018-09-10 2019-09-10 Methods of treating immunotherapy-related toxicity using a gm-csf antagonist

Publications (3)

Publication Number Publication Date
JP2022517461A true JP2022517461A (ja) 2022-03-09
JPWO2020055932A5 JPWO2020055932A5 (https=) 2022-09-21
JP2022517461A5 JP2022517461A5 (https=) 2022-09-21

Family

ID=69778357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512883A Pending JP2022517461A (ja) 2018-09-10 2019-09-10 Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法

Country Status (11)

Country Link
EP (1) EP3849572A4 (https=)
JP (1) JP2022517461A (https=)
KR (1) KR20210075090A (https=)
CN (1) CN113164520A (https=)
AU (1) AU2019340662A1 (https=)
BR (1) BR112021004489A2 (https=)
CA (1) CA3111804A1 (https=)
IL (1) IL281243A (https=)
MX (1) MX2021002856A (https=)
SG (1) SG11202102317PA (https=)
WO (1) WO2020055932A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240158467A1 (en) * 2018-10-31 2024-05-16 Humanigen, Inc. Materials and methods for treating cancer
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN118949031A (zh) * 2019-06-03 2024-11-15 基尼克萨制药股份有限公司 用gm-csf拮抗剂治疗癌症
WO2021204649A1 (en) * 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN113402620B (zh) * 2021-07-30 2021-12-10 中山大学 细胞因子联合嵌合抗原受体的融合蛋白及其应用
CN116887856A (zh) * 2022-01-20 2023-10-13 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用
CN114606237B (zh) * 2022-05-11 2025-10-28 上海优替济生生物医药有限公司 Gm-csf抑制剂及其用途
CN119144563B (zh) * 2023-11-24 2025-11-25 成都赛恩吉诺生物科技有限公司 表达gm-csf截短功能区片段的免疫工程细胞及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518886A (ja) * 2008-04-28 2011-06-30 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
JP2020536118A (ja) * 2017-10-02 2020-12-10 ヒューマニジェン，インコーポレイテッド Ｇｍ−ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
LT4461308T (lt) * 2012-07-13 2025-06-10 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo valdymas
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
US20190292246A1 (en) * 2016-11-03 2019-09-26 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia imhibitor
US10899831B2 (en) * 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
JP7411578B2 (ja) * 2018-06-01 2024-01-11 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 癌を治療するための物質及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518886A (ja) * 2008-04-28 2011-06-30 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
JP2020536118A (ja) * 2017-10-02 2020-12-10 ヒューマニジェン，インコーポレイテッド Ｇｍ−ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法

Also Published As

Publication number Publication date
EP3849572A2 (en) 2021-07-21
MX2021002856A (es) 2021-05-28
IL281243A (en) 2021-04-29
BR112021004489A2 (pt) 2021-07-20
CA3111804A1 (en) 2020-03-19
WO2020055932A2 (en) 2020-03-19
CN113164520A (zh) 2021-07-23
AU2019340662A1 (en) 2021-05-06
WO2020055932A9 (en) 2020-07-09
SG11202102317PA (en) 2021-04-29
WO2020055932A3 (en) 2020-05-22
EP3849572A4 (en) 2022-07-13
KR20210075090A (ko) 2021-06-22

Similar Documents

Publication Publication Date Title
JP7320498B2 (ja) Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
JP6847037B2 (ja) 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
JP2022517461A (ja) Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
JP6755866B2 (ja) Ｃｄ７３特異的結合分子及びその使用
CN110066338B (zh) 作为T细胞衔接器的双特异性IgG抗体
US10899831B2 (en) Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
JP2020517302A (ja) Ｃｄ１９に対するヒト化抗原結合ドメイン及び使用方法
CN116425876A (zh) Bcma结合分子及其使用方法
KR20220007584A (ko) 항-clec2d 항체 및 이의 사용 방법
US20210230262A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
CA3172120A1 (en) Chimeric antigen receptor specific for human cd45rc and uses thereof
US20210322547A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
US20220025034A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
KR20250025354A (ko) 항-ilt3 항체 및 이의 용도
US20210290677A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
EP4506368A1 (en) Bispecific antibody to human tim-3 and human cd39, and applications thereof
CN114616245B (zh) 一种抗cd38的抗体及其用途
US20240109973A1 (en) Cd40 binding molecules and uses thereof
TW202308688A (zh) 以gm-csf拮抗劑治療免疫療法相關毒性之方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240305